NCT00168779已完成4 期
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,185
- 试验地点
- 117
- 主要终点
- Mean seated trough cuff DBP and SBP
研究概览
简要总结
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent.
- •Age 18 years or older
- •Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
- •Seated cuff DBP of ? 95 mmHg at Visit 2 (baseline)
排除标准
- •Pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:
- •are not surgically sterile and/or
- •are nursing or pregnant
- •are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
- •Known or suspected secondary hypertension.
- •Mean seated SBP >= 180 mmHg or mean seated DBP >= 120 mmHg during any clinic visit prior to randomization.
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- •SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range, or
- •Serum creatinine > 3.0 mg/dL or creatinine clearance < 0.6 ml/sec.
- •Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
- •Clinically relevant hypokalemia or hyperkalemia.
- •Uncorrected volume depletion.
- •Uncorrected sodium depletion.
- •Primary aldosteronism.
- •Hereditary fructose intolerance.
- •Biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency.
- •Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
- •History of drug or alcohol dependency within six months prior to start of run-in period.
- •Chronic administration of any medications known to affect blood pressure, exc
结局指标
主要结局
Mean seated trough cuff DBP and SBP
时间窗: after 8 week
次要结局
- The percentage of patients responding to treatment based on in-clinic mean seated trough cuff measurements(after 8 week)
- The percentage of patients with uncontrolled hypertension(after 8 weeks)
- Change in the in-clinic mean seated cuff DBP and SBP at the one and three hour post dose time points(after 8 weeks)
研究者
研究点 (117)
Loading locations...
相似试验
已完成
4 期
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II PatientsHypertensionNCT00240448Boehringer Ingelheim1,109
已完成
3 期
A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate HypertensionHypertensionNCT00133185Boehringer Ingelheim31
终止
4 期
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsCoronary ArteriosclerosisHypertensionNCT00274105Boehringer Ingelheim22
已完成
4 期
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure MonitoringHypertensionNCT02242318Boehringer Ingelheim440
已完成
3 期
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant HypertensionHypertensionNCT00553267Boehringer Ingelheim947